Feed BCLI
BC

Brainstorm Cell Therapeutics Inc. BCLI · OTC

$0.78 +0.78% (+$0.01)

Market cap
$8.50M
Enterprise value
$9.85M
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/FCF
-
EV/EBITDA
-
ROIC
60.1%
Gross margin
-
Net margin
-
Dividend yield
-
Payout ratio
-
Net debt/EBITDA
-
Beta
0.24
Free float
70.5%

About the company

Brainstorm Cell Therapeutics Inc. (BCLI) is a biotechnology company focused on researching and developing therapies for neurological disorders. The company specializes in utilizing its proprietary technologies and methods for treating and improving the quality of life for patients suffering from neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS). Brainstorm Cell Therapeutics is developing innovative cell-based therapeutic approaches that offer hope for improving the health of those grappling with these serious diseases. Investors interested in the biotechnology sector and medical research may find the shares of Brainstorm Cell Therapeutics Inc. (BCLI) to be an intriguing investment opportunity.

Sector

Healthcare

Industry

Biotechnology

CEO

Chaim Lebovits

Employees

19

Headquarters

New York City

Valuation

Is today's price reasonable?

Growth and estimates

Is it growing, and what comes next?

Profitability and quality

How much of the revenue is left, and how well does the company use its capital?

Financial health

Can it carry its debt?

Capital and dividends

What does the company do with the money it earns?

Analysts

What do the professionals think, and is it changing?

Owners and insiders

Who holds the stock, and what is management doing?

Segments

Which part of the company is growing?

Peer comparison

How does it compare with similar companies?

Price and risk

How does the stock behave?

Statements

Every number

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.